Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Provided By PR Newswire
Last update: Nov 12, 2024
-Phase III trial enrolled a total of 480 patients with moderate to severe acne
-Topline results expected in the second quarter 2025
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.
Read more at prnewswire.comNASDAQ:SGMT (6/17/2025, 3:41:06 PM)
6.99
-0.41 (-5.54%)
Find more stocks in the Stock Screener
SGMT Latest News and Analysis
5 days ago - ChartmillHere are the top movers in Thursday's session.Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
13 days ago - ChartmillThese stocks are moving in today's pre-market sessionAs we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
